Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® (abemaciclib)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
How is diarrhoea with Verzenios® (abemaciclib) managed?
At the first sign of loose stools, start treatment with anti-diarrhoeal agents such as loperamide and increase oral liquids. Dose modifications are recommended in patients who develop ≥ Grade 2 diarrhoea.
Dose modification and management of diarrhoea
Diarrhoea is the most common adverse reaction associated with Abemaciclib and severe cases have been reported in clinical trials. Depending on the CTCAE Grade of the adverse reaction, a dose modification may be required.1
For complete information about the incidence and management of diarrhoea, please refer to the Verzenios Summary of Product Characteristics, in particular the sections
- 4.2 Posology and method of administration
- 4.4 Special warnings and precautions for use
- 4.8 Undesirable effects
Please find recommendations for dose modifications to manage diarrhoea presented in Management recommendations for diarrhoea.
References
1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2US Department of Health and Human Services; National Institutes of Health and National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.03. May 28, 2009. Updated June 14, 2010. Accessed April 7, 2025. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
Links to references and third-party websites are provided solely for your convenience and to facilitate easy access to the sources cited.
Date of Last Review: 30 October 2023